3 terminated. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 3 |
Follow Antineoplastic Agents: new trials by email Literature Review of Antineoplastic Agents trials Research Report on Antineoplastic Agents
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations BLU-451, Carboplatin, Pemetrexed - Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Blueprint Medicines Corporation | 103 | 2022-03-04 | 2025-02-10 |
| (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC BLU-701, osimertinib, carboplatin - Lung Neoplasm, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Blueprint Medicines Corporation | 20 | 2022-01-13 | 2023-06-18 |
| (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC BLU-945, osimertinib - Lung Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Blueprint Medicines Corporation | 177 | 2021-06-29 | 2025-02-10 |
Adenocarcinoma (3) · Bronchial Neoplasms (3) · Carcinoma (3) · Carcinoma, Bronchogenic (3) · Carcinoma, Non-Small-Cell Lung (3) · Lung Diseases (3) · Lung Neoplasms (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3) · Thoracic Neoplasms (3) · Neoplasms, Nerve Tissue (2) · Brain Neoplasms (1)
Bronchial Diseases (3) · Neoplasms, Glandular and Epithelial (3) · Brain Diseases (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Nervous System Diseases (1) · Nervous System Neoplasms (1)
Carboplatin (2) · Pemetrexed (2) · osimertinib (2)
Blueprint Medicines Corporation (3)
United States (3) · Canada (2) · Japan (2) · South Korea (2) · Taiwan (2) · France (1) · Netherlands (1) · Singapore (1) · Spain (1) · United Kingdom (1)